Angela Jeong1, Kiall Francis Suazo2, W Gibson Wood3, Mark D Distefano2, Ling Li1,3. 1. a Department of Experimental and Clinical Pharmacology , University of Minnesota , Minneapolis , MN , USA. 2. b Department of Chemistry , University of Minnesota , Minneapolis , MN , USA. 3. c Department of Pharmacology , University of Minnesota , Minneapolis , MN , USA.
Abstract
The mevalonate-isoprenoid-cholesterol biosynthesis pathway plays a key role in human health and disease. The importance of this pathway is underscored by the discovery that two major isoprenoids, farnesyl and geranylgeranyl pyrophosphate, are required to modify an array of proteins through a process known as protein prenylation, catalyzed by prenyltransferases. The lipophilic prenyl group facilitates the anchoring of proteins in cell membranes, mediating protein-protein interactions and signal transduction. Numerous essential intracellular proteins undergo prenylation, including most members of the small GTPase superfamily as well as heterotrimeric G proteins and nuclear lamins, and are involved in regulating a plethora of cellular processes and functions. Dysregulation of isoprenoids and protein prenylation is implicated in various disorders, including cardiovascular and cerebrovascular diseases, cancers, bone diseases, infectious diseases, progeria, and neurodegenerative diseases including Alzheimer's disease (AD). Therefore, isoprenoids and/or prenyltransferases have emerged as attractive targets for developing therapeutic agents. Here, we provide a general overview of isoprenoid synthesis, the process of protein prenylation and the complexity of prenylated proteins, and pharmacological agents that regulate isoprenoids and protein prenylation. Recent findings that connect isoprenoids/protein prenylation with AD are summarized and potential applications of new prenylomic technologies for uncovering the role of prenylated proteins in the pathogenesis of AD are discussed.
The mevalonate-n class="Chemical">isoprenoid-cholesterol biosynthesis pathway plays a key role in human health and disease. The importance of this pathway is underscored by the discovery that two major isoprenoids, farnesyl and geranylgeranyl pyrophosphate, are required to modify an array of proteins through a process known as protein prenylation, catalyzed by prenyltransferases. The lipophilic prenyl group facilitates the anchoring of proteins in cell membranes, mediating protein-protein interactions and signal transduction. Numerous essential intracellular proteins undergo prenylation, including most members of the small GTPase superfamily as well as heterotrimeric G proteins and nuclear lamins, and are involved in regulating a plethora of cellular processes and functions. Dysregulation of isoprenoids and protein prenylation is implicated in various disorders, including cardiovascular and cerebrovascular diseases, cancers, bone diseases, infectious diseases, progeria, and neurodegenerative diseases including Alzheimer's disease (AD). Therefore, isoprenoids and/or prenyltransferases have emerged as attractive targets for developing therapeutic agents. Here, we provide a general overview of isoprenoid synthesis, the process of protein prenylation and the complexity of prenylated proteins, and pharmacological agents that regulate isoprenoids and protein prenylation. Recent findings that connect isoprenoids/protein prenylation with AD are summarized and potential applications of new prenylomic technologies for uncovering the role of prenylated proteins in the pathogenesis of AD are discussed.
Entities:
Keywords:
Alzheimer’s disease; Isoprenoids; bisphosphonates; prenylomics; prenyltransferase inhibitors; protein prenylation; small GTPases; statins
Authors: Joungil Choi; Allan I Levey; Susan T Weintraub; Howard D Rees; Marla Gearing; Lih-Shen Chin; Lian Li Journal: J Biol Chem Date: 2004-01-13 Impact factor: 5.157
Authors: Perry G Ridge; Celeste M Karch; Simon Hsu; Ivan Arano; Craig C Teerlink; Mark T W Ebbert; Josue D Gonzalez Murcia; James M Farnham; Anna R Damato; Mariet Allen; Xue Wang; Oscar Harari; Victoria M Fernandez; Rita Guerreiro; Jose Bras; John Hardy; Ronald Munger; Maria Norton; Celeste Sassi; Andrew Singleton; Steven G Younkin; Dennis W Dickson; Todd E Golde; Nathan D Price; Nilüfer Ertekin-Taner; Carlos Cruchaga; Alison M Goate; Christopher Corcoran; JoAnn Tschanz; Lisa A Cannon-Albright; John S K Kauwe Journal: Genome Med Date: 2017-11-29 Impact factor: 11.117
Authors: Vijay R Varma; H Büşra Lüleci; Anup M Oommen; Sudhir Varma; Chad T Blackshear; Michael E Griswold; Yang An; Jackson A Roberts; Richard O'Brien; Olga Pletnikova; Juan C Troncoso; David A Bennett; Tunahan Çakır; Cristina Legido-Quigley; Madhav Thambisetty Journal: NPJ Aging Mech Dis Date: 2021-06-01